Skip to main content

At Sobi North America, we work to make available medicines that transform the lives of people with rare and debilitating diseases. Inspired by caring, powered by science, Sobi is dedicated to ensuring every eligible person is given an opportunity to benefit from our approved medicines. 

In the U.S., for a particular disease to be labeled “rare,” there are fewer than 200,000 people with that diagnosis. This presents specific scientific, medical and commercial challenges to treating an extremely small patient population.  It starts with understanding the biology of the disease and discovering molecules that may work as a treatment. Then, there are often complex manufacturing processes required to make the drug, as well as clinical trials, regulatory approvals and negotiating access for the people who need the treatment.

At Sobi, we believe every disease, every patient is worth a cure. That’s why we work tirelessly to bring treatments to people with a rare and severe diagnosis. 

Such treatments are referred to as “orphan drugs,” intended to treat diseases so rare that companies would be reluctant to develop them under normal market conditions.

Sobi will continue to capture value from its pipeline, by concentrating on mid- and late-stage opportunities that help address unmet medical needs focused on hematology, immunology and specialty care. Greater awareness and more available medicines mean the world is looking brighter every day for people suffering from rare diseases.

State Price Disclosures for All Products

DOPTELET (avatrombopag)

GAMIFANT (emapalumab-lzsg)

KEPIVANCE (palifermin)

KINERET (anakinra)

ORFADIN (nitisinone)

SYNAGIS (palivizumab)

VONJO (pacritinib)